AbbVie took Shire home with her<\/span><\/a><\/span><\/strong> and to do so it will disburse $54.7 billion, of which 46% in cash and the remainder in treasury shares. Considering that Shire currently has a turnover of about 5 billion a year, we are at 11 times the turnover. The transaction will close in the fourth quarter of 2014.<\/p>\n With this merger, AbbVie intends to reduce its tax burden, in Ireland taxes<\/strong><\/span><\/a><\/span> they are significantly lower than in the USA (12.5% against 35%). So the pharmaceutical giant based in Campovedre confirms the growing trend and the willingness to continue investing, while the rumors coming from its 'sister' Abbott, also based in the Campoverde site, are alarming after the US pharmaceutical group Mylan has signed an agreement<\/strong><\/span><\/a><\/span> to acquire from rival and compatriot Abbott Laboratories<\/strong><\/span><\/a><\/span> rights to 100 generic drugs for $5.3 billion in stock. Thanks to this agreement, some productions will be moved to the Netherlands, effectively emptying part of the Campoverde plant. To throw the'alarm is the CISL<\/strong><\/span><\/a><\/span>, which already feared the split of the company into two branches, Abbott and Abbvie, which took place in 2012.<\/p>\n Related news<\/i>: http:\/\/www.fedaiisf.it\/Start\/HDefault.aspx?Newsid=9528<\/a><\/p>\n